Repositioning baloxavir marboxil as VISTA agonist that ameliorates experimental asthma.

ABSTRACT: V-type immunoglobulin domain-containing suppressor of T-cell activation (VISTA), a novel negative checkpoint regulator, plays an essential role in allergic pulmonary inflammation in mice. Treatment with a VISTA agonistic antibody could significantly improve asthma symptoms. Thus, for allergic asthma treatment, VISTA targeting may be a compelling approach. In this study, we examined the functional mechanism of VISTA in allergic pulmonary inflammation and screened the FDA-approved drugs for VISTA agonists. By using mass cytometry (CyTOF), we found that VISTA deficiency primarily increased lung macrophage infiltration in the OVA-induced asthma model, accompanied by an increased proportion of M1 macrophages (CD11b⁺F4/80⁺CD86⁺) and a decreased proportion of M2 m

SUBMITTER: Di JW 

PROVIDER: S-EPMC10858940 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature